Tagged with Thermo Fisher

Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…

Global While many diagnostics companies have suffered from the decline in COVID-19 testing since the pandemic, the sector, expected to grow from USD 210.58 billion to reach USD 284.38 billion by 2033, continues to thrive as it brings forward new levels of innovation and precision for a range of diseases. We…

Mexico Cecilia Moreno, from the PPD™ clinical research business of Thermo Fisher Scientific, highlights Mexico’s growing role in clinical research, supported by regulatory advancements and a skilled workforce. Moreno emphasizes the potential for expanding clinical trials in Mexico, enhancing patient access to innovative therapies, and leveraging the country’s strategic advantages in…

Mexico Francisco Chavez from Thermo Fisher Scientific explains the company’s global mission to advance science and healthcare, with a particular focus on Latin America. Chavez highlights Thermo Fisher’s significant investment in R&D and its strategic approach to addressing regional healthcare challenges through public-private partnerships.   Our commitment is to create a…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Global The global contract research organization (CRO) market is estimated to be worth USD 76.6 billion in 2023 and is projected to reach USD 127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028. Much of this growth is due to the need for novel clinical trial…

China A roundup of some of the biggest healthcare and pharma news from China, including the country’s struggle with a rampant COVID-19 outbreak and the external concern that surrounds it, China Meheco’s Paxlovid contract, Boston Scientific’s majority stake in Chinese medtech Acotec, Gracell Biotechnologies’ CAR-T therapy phase I trial 100 percent…

Global Driven by increased demand from Big Pharma, mid-caps, and biotechs for outsourcing services, the USD 70 billion global contract research organisation (CRO) market is predicted to grow at a CAGR of between 11 and 12 percent over the next five to seven years, with differing estimates placing its total size…

China The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility.   China pharma shares fall as western rivals lead in vaccine trials https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b…

China Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China, the importance of entrepreneurial thinking and agility to the China market, the significant investments they have made here, and his…